应对与减轻COVID-19相关肺曲霉病的风险
本文指出COVID-19相关肺曲霉病(CAPA)病例报告日益增多,治疗COVID-19相关肺病患者的医生需主动考虑这类真菌合并感染。重症COVID-19以病毒性肺炎继发急性呼吸窘迫综合征(ARDS)为特征,可能需要机械通气或体外膜氧合。临床医生对细菌合并感染保持警惕,但真菌合并感染尤其是CAPA的风险仍被低估。
要点
- CAPA病例报告日益增多,需主动考虑真菌合并感染。
- 重症COVID-19可继发ARDS,需机械通气或ECMO。
- 真菌合并感染尤其CAPA的风险仍被低估。
核心结论
- COVID-19相关肺曲霉病(CAPA)病例报告日益增多,需主动考虑这类真菌合并感染。
- 真菌合并感染尤其CAPA的风险仍被低估。
主要发现
- 重症COVID-19以病毒性肺炎继发ARDS为特征,可能需要机械通气或体外膜氧合。
- 近期综述发现72%的COVID-19患者接受了抗菌治疗。
临床怎么用
- 治疗COVID-19相关肺病患者的医生需主动考虑CAPA这类真菌合并感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections https://bit.ly/3feuGsQ The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1]. Severe COVID-19 is characterised by acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.
引用
- Armstrong-James D, Youngs J, Bicanic T, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020. PMID: 32703771. doi:10.1183/13993003.02554-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。